For the past few months, CVS Caremark has declined to add a groundbreaking HIV prevention drug from Gilead Sciences to its formularies. Clinical trials showed the twice-a-year injectable, called Yeztugo, was highly effective in preventing the infectious disease, prompting enthusiasm about combating HIV globally. But the pharmacy benefits manager has argued that the $28,000 price tag…
For the past three months, CVS Caremark has resisted adding a new Gilead Sciences HIV prevention drug to its formularies, repeatedly explaining there are “clinical, financial, and regulatory considerations” that must be reviewed before it will take that step. Not surprisingly, though, what the largest pharmacy benefits manager in the U.S. simply wants is a…
After months of tense negotiations, Gilead Sciences has agreed not to boost prices next year for HIV medicines that are sold to state AIDS Drug Assistance Programs, an outcome that lessens the financial strains for agencies that are relied on by many people on low incomes. Earlier this year, the company sought to boost prices…
In an ambitious bid to prevent the spread of HIV, several prominent global health organizations will provide backing for two generic manufacturers to produce and distribute a low-cost version of a groundbreaking Gilead Sciences drug in dozens of poor countries. The arrangements call for Dr. Reddy’s Laboratories and Hetero — two of the largest purveyors…
The Centers for Disease Control and Prevention is recommending that a groundbreaking medicine from Gilead Sciences should be used for HIV prevention, a move that was hailed by dozens of patient advocacy groups that are now urging CVS Health to reverse a recent decision not to cover the drug. The move comes three months after…
Gilead Sciences, the largest maker of HIV medicines, is seeking to boost prices significantly for several treatments that are widely distributed by state AIDS Drug Assistance Programs. And the move is adding to financial uncertainty for the programs on top of concerns prompted by Trump administration funding cuts. The company recently told the state programs…